Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07093177Recruiting
Telehealth exercise program for rural men with advanced prostate cancer
This trial tests a telehealth exercise program for men with advanced prostate cancer who live in rural areas. It aims to improve health and quality of life through supervised exercise sessions at home.
Salt Lake City, UtahAges 18 years+ - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT07086469RecruitingPhase 2
Surufatinib plus chemo-immunotherapy before chemoradiation for advanced esophageal cancer
This trial tests a new combination of treatments for people with advanced esophageal cancer that can't be removed by surgery. It uses a targeted therapy called surufatinib along with chemo-immunotherapy and radiation to see if it can shrink the tumor before further treatment.
Guangzhou, GuangdongAges 18–80 - NCT07086300Recruiting
Acupuncture with immunotherapy for older lung cancer patients
This trial tests whether adding electroacupuncture (a gentle, needle-based therapy) to a standard immunotherapy drug (PD-1 inhibitor) can help older adults with advanced lung cancer. It may improve treatment response and quality of life.
Tianjin, Tianjin MunicipalityAges 65–100 - NCT05362760RecruitingPhase 4
Abemaciclib plus hormone therapy, with digital side-effect tracking
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
AalenAges 18 years+ - NCT06251115Recruiting
Study of QY-1-T for advanced HBV-related liver cancer
This study tests a new treatment called QY-1-T for people with advanced liver cancer related to hepatitis B. It is for patients who have already tried other standard treatments and have a certain genetic marker (HLA-A*11:01).
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06866041Recruiting
Prostate cancer markers and imaging for low-risk patients on active surveillance
This trial looks for new markers and advanced scans to better predict which low-risk prostate cancers might grow. If you have low-risk prostate cancer and are managing it with active surveillance, researchers want to see if PSMA-PET scans and tissue markers can give earlier warning of progression.
Milan, ItalyAges 45–80 - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT07075939Recruiting
Centralized care for ovarian cancer: a study of outcomes
This study looks at whether having ovarian cancer care coordinated by a special team (Multidisciplinary Tumor Board) leads to better outcomes. It reviews records of patients treated between 2018 and 2023 to understand how centralization affects their health.
Carpi, ModenaAges 18–99 - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07080216RecruitingPhase 1/Phase 2
Study of ZG005 and Gecacitinib for advanced cervical cancer
This trial tests a combination of two new drugs, ZG005 and Gecacitinib, for people with advanced cervical cancer that has spread or come back. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18–75 - NCT07079475RecruitingPhase 1/Phase 2
Study of two targeted pills for EGFR-mutated lung cancer
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07085234RecruitingPhase 2
New drug combo before radiation for advanced nasopharyngeal cancer
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy before standard radiation for advanced nasopharyngeal cancer. It aims to shrink tumors and improve outcomes.
Xiamen, FujianAges 18–65 - NCT07085572RecruitingPhase 2
Cemiplimab for maintenance in adrenocortical cancer
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Brescia, BresciaAges 18 years+ - NCT05970497RecruitingPhase 1/Phase 2
KB707 trial for advanced solid tumors after other treatments
This early-stage trial tests KB707 in people with locally advanced or metastatic solid tumors that have not responded well to standard treatments. If you qualify, you may receive KB707 to see how well it can shrink tumors or control the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06343064RecruitingPhase 1/Phase 2
Vebreltinib plus PLB1004 for EGFR-mutant lung cancer with MET changes
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06574347RecruitingPhase 2
Two targeted drugs for EGFR-mutated, MET-high lung cancer
This trial tests a combination of two targeted drugs (vebreltinib and PLB1004) as the first treatment for people with a specific type of advanced lung cancer that has both an EGFR mutation and high MET protein. It may offer a new option for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT06982079RecruitingPhase 3
SGLT2 inhibitors for advanced kidney disease
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
CairoAges 18 years+ - NCT07067138Recruiting
Genetic testing to guide treatment for advanced breast cancer
This study looks at the genes in your cancer to find a treatment that might work better for you. It tests your tumor sample to match you with a drug that targets your cancer's specific weaknesses.
Bethesda, MarylandAges 18–120 - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07069062RecruitingPhase 1/Phase 2
Study of HY0001a for Advanced Solid Tumors
This trial tests a new drug, HY0001a, for people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein on some cancer cells, and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07066267Recruiting
Mitochondria from fat cells to boost IVF eggs
This study tests if giving your eggs a boost from your own fat-cell mitochondria can improve chances of a healthy pregnancy for people who have had multiple failed IVF cycles. You'll donate a small amount of fat through liposuction, and the mitochondria from those cells will be added to your eggs before fertilization.
ColomboAges 29–39
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.